{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=FOLFIRI+%28Fluorouracil+%285-FU%29%2C+leucovorin%2C+irinotecan%29",
    "query": {
      "intervention": "FOLFIRI (Fluorouracil (5-FU), leucovorin, irinotecan)"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 112,
    "total_pages": 12,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=FOLFIRI+%28Fluorouracil+%285-FU%29%2C+leucovorin%2C+irinotecan%29&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-10T16:58:28.883Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05379595",
      "title": "A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced or Metastatic Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "Amivantamab IV",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fluorouracil",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Leucovorin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Oxaliplatin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Irinotecan",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Amivantamab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 225,
      "start_date": "2022-07-29",
      "completion_date": "2031-05-11",
      "has_results": false,
      "last_update_posted_date": "2026-09-25",
      "last_synced_at": "2026-10-10T16:58:28.883Z",
      "location_count": 14,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 9 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05379595"
    },
    {
      "nct_id": "NCT03798626",
      "title": "Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Colorectal Cancer",
        "Gastroesophageal Cancer",
        "Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Gevokizumab",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Modified FOLFOX6",
          "type": "DRUG"
        },
        {
          "name": "FOLFIRI",
          "type": "DRUG"
        },
        {
          "name": "Ramucirumab",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Cabozantinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 167,
      "start_date": "2019-05-22",
      "completion_date": "2025-02-05",
      "has_results": false,
      "last_update_posted_date": "2026-04-01",
      "last_synced_at": "2026-10-10T16:58:28.883Z",
      "location_count": 3,
      "location_summary": "Los Angeles, California • St Louis, Missouri • Nashville, Tennessee",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03798626"
    },
    {
      "nct_id": "NCT01888978",
      "title": "Molecularly Tailored Therapy for Pancreas Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "Gem-OX",
          "type": "DRUG"
        },
        {
          "name": "Gem-5FU",
          "type": "DRUG"
        },
        {
          "name": "Gem-Tax",
          "type": "DRUG"
        },
        {
          "name": "Modified FOLFOX-6",
          "type": "DRUG"
        },
        {
          "name": "Ox-Tax",
          "type": "DRUG"
        },
        {
          "name": "FOLFIRI",
          "type": "DRUG"
        },
        {
          "name": "Tax-Iri",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Georgetown University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 19,
      "start_date": "2012-12",
      "completion_date": "2018-01-24",
      "has_results": false,
      "last_update_posted_date": "2018-04-09",
      "last_synced_at": "2026-10-10T16:58:28.883Z",
      "location_count": 2,
      "location_summary": "Washington D.C., District of Columbia • Olney, Maryland",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Olney",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01888978"
    },
    {
      "nct_id": "NCT00851045",
      "title": "Ph II Trial of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Second-line Treatment of Metastatic Colorectal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Colorectal Cancer (CRC)"
      ],
      "interventions": [
        {
          "name": "Irinotecan",
          "type": "DRUG"
        },
        {
          "name": "5-Fluorouracil (bolus)",
          "type": "DRUG"
        },
        {
          "name": "5-Fluorouracil (infusional)",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin calcium",
          "type": "DRUG"
        },
        {
          "name": "CT-322",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab Placebo (saline solution)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2009-10",
      "completion_date": "2011-10",
      "has_results": false,
      "last_update_posted_date": "2015-10-12",
      "last_synced_at": "2026-10-10T16:58:28.883Z",
      "location_count": 12,
      "location_summary": "Tucson, Arizona • Fountain Valley, California • Riverside, California + 9 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Riverside",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00851045"
    },
    {
      "nct_id": "NCT01183780",
      "title": "A Study in Second Line Metastatic Colorectal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "Ramucirumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Irinotecan",
          "type": "DRUG"
        },
        {
          "name": "Folinic Acid",
          "type": "DRUG"
        },
        {
          "name": "5-Fluorouracil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1072,
      "start_date": "2010-12-02",
      "completion_date": "2016-06-20",
      "has_results": true,
      "last_update_posted_date": "2019-09-25",
      "last_synced_at": "2026-10-10T16:58:28.883Z",
      "location_count": 92,
      "location_summary": "Sedona, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 89 more",
      "locations": [
        {
          "city": "Sedona",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01183780"
    },
    {
      "nct_id": "NCT02890355",
      "title": "FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Pancreatic Adenocarcinoma",
        "Recurrent Pancreatic Carcinoma",
        "Stage IV Pancreatic Cancer AJCC v6 and v7"
      ],
      "interventions": [
        {
          "name": "Fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "Irinotecan Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Leucovorin Calcium",
          "type": "DRUG"
        },
        {
          "name": "Veliparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 123,
      "start_date": "2016-10-27",
      "completion_date": "2021-10-21",
      "has_results": true,
      "last_update_posted_date": "2026-05-20",
      "last_synced_at": "2026-10-10T16:58:28.883Z",
      "location_count": 783,
      "location_summary": "Mobile, Alabama • Anchorage, Alaska • Hot Springs, Arkansas + 507 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02890355"
    },
    {
      "nct_id": "NCT00323011",
      "title": "FOLFIRI + Bevacizumab With or Without Dalteparin in First Line Treatment of Advanced Colorectal Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "Fragmin, 5-Fluorouracil, Folinic Acid, irinotecan, bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Southern California",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2006-05",
      "completion_date": "2007-11",
      "has_results": false,
      "last_update_posted_date": "2014-05-21",
      "last_synced_at": "2026-10-10T16:58:28.883Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00323011"
    },
    {
      "nct_id": "NCT03803553",
      "title": "Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Metastatic Colon Cancer",
        "Stage III Colon Cancer"
      ],
      "interventions": [
        {
          "name": "FOLFIRI Protocol",
          "type": "DRUG"
        },
        {
          "name": "ACTIVE SURVEILLANCE",
          "type": "OTHER"
        },
        {
          "name": "Nivolumab Protocol",
          "type": "DRUG"
        },
        {
          "name": "Encorafenib/Binimetinib/Cetuximab Protocol",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab + Pertuzumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 400,
      "start_date": "2020-04-16",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2026-09-09",
      "last_synced_at": "2026-10-10T16:58:28.883Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts • New York, New York",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03803553"
    },
    {
      "nct_id": "NCT01605344",
      "title": "Crossover Evaluation of Effect of Atorvastatin on PK of Irinotecan in CRC Patients Receiving FOLFIRI",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Adenocarcinoma of the Colon or Rectum"
      ],
      "interventions": [
        {
          "name": "FOLFIRI.",
          "type": "DRUG"
        },
        {
          "name": "Atorvastatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "UNC Lineberger Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2012-04",
      "completion_date": "2014-07",
      "has_results": false,
      "last_update_posted_date": "2014-02-27",
      "last_synced_at": "2026-10-10T16:58:28.883Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01605344"
    },
    {
      "nct_id": "NCT04553692",
      "title": "Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor",
        "Colorectal Cancer",
        "Non Hodgkin Lymphoma",
        "Sarcoma",
        "Chondrosarcoma",
        "Small Lymphocytic Lymphoma",
        "Chronic Lymphocytic Leukemia",
        "Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Aplitabart (IGM-8444)",
          "type": "DRUG"
        },
        {
          "name": "FOLFIRI",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab (and approved biosimilars)",
          "type": "DRUG"
        },
        {
          "name": "Birinapant",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Azacitidine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "IGM Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 272,
      "start_date": "2020-09-23",
      "completion_date": "2025-01-20",
      "has_results": false,
      "last_update_posted_date": "2025-03-28",
      "last_synced_at": "2026-10-10T16:58:28.883Z",
      "location_count": 37,
      "location_summary": "Phoenix, Arizona • Duarte, California • Los Alamitos, California + 29 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Alamitos",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04553692"
    }
  ]
}